Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
5.62
-0.07 (-1.23%)
Nov 12, 2025, 12:35 PM EST - Market open
Aquestive Therapeutics Revenue
Aquestive Therapeutics had revenue of $12.81M in the quarter ending September 30, 2025, a decrease of -5.43%. This brings the company's revenue in the last twelve months to $43.40M, down -26.32% year-over-year. In the year 2024, Aquestive Therapeutics had annual revenue of $57.56M with 13.80% growth.
Revenue (ttm)
$43.40M
Revenue Growth
-26.32%
P/S Ratio
13.01
Revenue / Employee
$305,613
Employees
142
Market Cap
685.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.56M | 6.98M | 13.80% |
| Dec 31, 2023 | 50.58M | 2.90M | 6.09% |
| Dec 31, 2022 | 47.68M | -3.15M | -6.20% |
| Dec 31, 2021 | 50.83M | 4.98M | 10.87% |
| Dec 31, 2020 | 45.85M | -6.76M | -12.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AQST News
- 5 days ago - Aquestive Therapeutics, Inc. (AQST) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development Transcript - Seeking Alpha
- 6 days ago - Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET - GlobeNewsWire
- 4 weeks ago - Aquestive Therapeutics: A Measured Bet - Seeking Alpha
- 5 weeks ago - Aquestive Therapeutics Broadens Patent Estate for Anaphylm™ - GlobeNewsWire
- 2 months ago - Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst - Seeking Alpha
- 3 months ago - Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock - GlobeNewsWire
- 3 months ago - Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film - GlobeNewsWire